Drug Profile

Mesenchymal stem cell therapy - INmune Bio

Alternative Names: CORDStrom

Latest Information Update: 24 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator INmune Bio
Class Stem cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Epidermolysis bullosa dystrophica
New Molecular Entity No

Highest Development Phases

Phase II Epidermolysis bullosa dystrophica

Most Recent Events

16 Apr 2025 INmune Bio has patents pending for Mesenchymal stem cell therapy in USA
15 Apr 2025 INmune Bio and Cell and Gene Therapy Catapult agree to co-promote CORDStrom™ for Epidermolysis bullosa dystrophica
27 Mar 2025 INmune Bio plans a 12-month open label study at GOSH

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com